Distribution And Supply Agreements	12 Months Ended
Dec. 31, 2011
Distribution And Supply Agreements [Abstract]
Distribution And Supply Agreements	Note 11 - Distribution and Supply Agreements: We enter into marketing and license agreements with third parties to market new products and technologies in an effort to broaden our product line. To date, we have entered into and are selling product through several of these agreements. We recognize the expense associated with these agreements as part of cost of goods sold. We believe that the following agreements are those that are the most significant to our business. *Generic Business Related* AstraZeneca LP On August 10, 2006, Par and AstraZeneca entered into a distribution agreement, pursuant to which Par is marketing metoprolol succinate, supplied and licensed from AstraZeneca. Under this agreement, AstraZeneca has agreed to manufacture the product and Par has agreed to pay AstraZeneca a percentage of Par's profit for the product, as defined in the agreement. On June 24, 2011, Par and AstraZeneca entered into a distribution agreement, pursuant to which Par is marketing budesonide, a generic version of Entocort® EC, supplied and licensed from AstraZeneca. Under this agreement, AstraZeneca has agreed to manufacture the product and Par has agreed to pay AstraZeneca a percentage of Par's profit for the product, as defined in the agreement. GlaxoSmithKline plc ("GSK") On November 10, 2006 Par and GSK and certain of its affiliates entered into a supply and distribution agreement, pursuant to which Par is marketing certain products containing sumatriptan. Under the agreement, GSK supplies Par and Par markets the product in the U.S. In addition to the agreed upon price for the product, Par pays GSK a percentage of Par's net sales of the product, as defined in the agreement. This agreement expired on November 2011, upon the three year anniversary of the product launch. On February 9, 2009, Par and GSK (formerly Reliant Pharmaceuticals, Inc) entered into a non-exclusive licensing agreement to market propafenone HCL, a generic version of Rythmol®SR . Under the agreement, Par markets, sells and distributes the product and pays GSK a percentage of Par's profit for the product, as defined in the agreement. Par commenced sales in January 2011. SVC Pharma LP On June 27, 2008 Par and SVC entered into a license and distribution agreement for dronabinol. SVC granted Par the exclusive right and license to market, distribute and sell dronabinol in the United States for a term of approximately 10 years. Par shares net product margin as contractually defined on sales of dronabinol with SVC. Par is responsible for distribution, collections, and returns, while SVC is responsible for supplying dronabinol to Par for distribution. Novel Laboratories, Inc. On February 11, 2009, Par and Novel entered into a Manufacturing Agreement, pursuant to which Novel is providing certain manufacturing services related to tramadol ER. Under the agreement, Par markets the product and pays Novel a percentage of profits of the product, as defined in the agreement. Par commenced sales of the product in November 2009 after a favorable court ruling. Tris Pharma, Inc. In November 2009, Par entered into a License and Supply agreement with Tris Pharma to market Hydrocodone polistirex and chlorpheniramine polistirex (CIII) ER oral suspension, a generic version of UCB's Tussionex^®. Under the agreement, Tris manufactures the product and Par pays Tris a percentage of Par's net profits of the product, as defined in the agreement. Par commenced sales of the product in October 2010 upon final FDA approval. Payables Due To Supply and Distribution Agreement Partners Pursuant to these distribution agreements, we pay our partners a percentage of gross profits or a percentage of net sales, in accordance with contractual terms of the underlying agreements. As of December 31, 2011, we had payables due to distribution agreement partners of $69,359 thousand and $25,310 thousand as of December 31, 2010.

Note 11 - Distribution and Supply Agreements:

We enter into marketing and license agreements with third parties to market new products and technologies in an effort to broaden our product line. To date, we have entered into and are selling product through several of these agreements. We recognize the expense associated with these agreements as part of cost of goods sold. We believe that the following agreements are those that are the most significant to our business.

Generic Business Related

AstraZeneca LP

On August 10, 2006, Par and AstraZeneca entered into a distribution agreement, pursuant to which Par is marketing metoprolol succinate, supplied and licensed from AstraZeneca. Under this agreement, AstraZeneca has agreed to manufacture the product and Par has agreed to pay AstraZeneca a percentage of Par's profit for the product, as defined in the agreement.

On June 24, 2011, Par and AstraZeneca entered into a distribution agreement, pursuant to which Par is marketing budesonide, a generic version of Entocort® EC, supplied and licensed from AstraZeneca. Under this agreement, AstraZeneca has agreed to manufacture the product and Par has agreed to pay AstraZeneca a percentage of Par's profit for the product, as defined in the agreement.

GlaxoSmithKline plc ("GSK")

On November 10, 2006 Par and GSK and certain of its affiliates entered into a supply and distribution agreement, pursuant to which Par is marketing certain products containing sumatriptan. Under the agreement, GSK supplies Par and Par markets the product in the U.S. In addition to the agreed upon price for the product, Par pays GSK a percentage of Par's net sales of the product, as defined in the agreement. This agreement expired on November 2011, upon the three year anniversary of the product launch.

On February 9, 2009, Par and GSK (formerly Reliant Pharmaceuticals, Inc) entered into a non-exclusive licensing agreement to market propafenone HCL, a generic version of Rythmol®SR . Under the agreement, Par markets, sells and distributes the product and pays GSK a percentage of Par's profit for the product, as defined in the agreement. Par commenced sales in January 2011.

SVC Pharma LP

On June 27, 2008 Par and SVC entered into a license and distribution agreement for dronabinol. SVC granted Par the exclusive right and license to market, distribute and sell dronabinol in the United States for a term of approximately 10 years. Par shares net product margin as contractually defined on sales of dronabinol with SVC. Par is responsible for distribution, collections, and returns, while SVC is responsible for supplying dronabinol to Par for distribution.

Novel Laboratories, Inc.

On February 11, 2009, Par and Novel entered into a Manufacturing Agreement, pursuant to which Novel is providing certain manufacturing services related to tramadol ER. Under the agreement, Par markets the product and pays Novel a percentage of profits of the product, as defined in the agreement. Par commenced sales of the product in November 2009 after a favorable court ruling.

Tris Pharma, Inc.

In November 2009, Par entered into a License and Supply agreement with Tris Pharma to market Hydrocodone polistirex and chlorpheniramine polistirex (CIII) ER oral suspension, a generic version of UCB's Tussionex^®. Under the agreement, Tris manufactures the product and Par pays Tris a percentage of Par's net profits of the product, as defined in the agreement. Par commenced sales of the product in October 2010 upon final FDA approval.

Payables Due To Supply and Distribution Agreement Partners

Pursuant to these distribution agreements, we pay our partners a percentage of gross profits or a percentage of net sales, in accordance with contractual terms of the underlying agreements. As of December 31, 2011, we had payables due to distribution agreement partners of $69,359 thousand and $25,310 thousand as of December 31, 2010.